Incyte Corporation reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve litigation regarding Medicaid rebate rules for Opzelura (ruxolitinib) cream. The settlement prevents CMS from treating Opzelura as a line extension of Jakafi, resulting in a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026. Incyte Corporation is a biotechnology company that develops and commercializes therapeutic products.
